These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35618478)

  • 21. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
    Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
    Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At.
    Vaidyanathan G; Affleck DJ; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2003 May; 30(4):351-9. PubMed ID: 12767391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
    Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
    Vaidyanathan G; Jestin E; Olafsen T; Wu AM; Zalutsky MR
    Nucl Med Biol; 2009 Aug; 36(6):671-80. PubMed ID: 19647173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Efficacy of
    Dekempeneer Y; Caveliers V; Ooms M; Maertens D; Gysemans M; Lahoutte T; Xavier C; Lecocq Q; Maes K; Covens P; Miller BW; Bruchertseifer F; Morgenstern A; Cardinaels T; D'Huyvetter M
    Mol Pharm; 2020 Sep; 17(9):3553-3566. PubMed ID: 32787284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-Succinimidyl 3-((4-(4-[(18)F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([(18)F]SFBTMGMB): a residualizing label for (18)F-labeling of internalizing biomolecules.
    Vaidyanathan G; McDougald D; Choi J; Pruszynski M; Koumarianou E; Zhou Z; Zalutsky MR
    Org Biomol Chem; 2016 Jan; 14(4):1261-71. PubMed ID: 26645790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Efficient Method for Labeling Single Domain Antibody Fragments with
    Zhou Z; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Bioconjug Chem; 2018 Dec; 29(12):4090-4103. PubMed ID: 30384599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiosynthesis and preclinical evaluations of [
    Tian R; Kong J; He Y; Xu G; Chen T; Han J
    Am J Nucl Med Mol Imaging; 2024; 14(3):175-181. PubMed ID: 39027646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery.
    Kijanka M; Warnders FJ; El Khattabi M; Lub-de Hooge M; van Dam GM; Ntziachristos V; de Vries L; Oliveira S; van Bergen En Henegouwen PM
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1718-29. PubMed ID: 23778558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I Trial of
    D'Huyvetter M; Vos J; Caveliers V; Vaneycken I; Heemskerk J; Duhoux FP; Fontaine C; Vanhoeij M; Windhorst AD; Aa FV; Hendrikse NH; Eersels JLE; Everaert H; Gykiere P; Devoogdt N; Raes G; Lahoutte T; Keyaerts M
    J Nucl Med; 2021 Aug; 62(8):1097-1105. PubMed ID: 33277400
    [No Abstract]   [Full Text] [Related]  

  • 32.
    Zhao L; Gong J; Qi Q; Liu C; Su H; Xing Y; Zhao J
    Int J Nanomedicine; 2023; 18():1915-1925. PubMed ID: 37064291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and In Vitro Function of Anti-Breast Cancer Llama-Based Single Domain Antibody VHH Expressed in Tobacco Plants.
    Park SR; Lee JH; Kim K; Kim TM; Lee SH; Choo YK; Kim KS; Ko K
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32079309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (18)F-nanobody for PET imaging of HER2 overexpressing tumors.
    Xavier C; Blykers A; Vaneycken I; D'Huyvetter M; Heemskerk J; Lahoutte T; Devoogdt N; Caveliers V
    Nucl Med Biol; 2016 Apr; 43(4):247-52. PubMed ID: 27067045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of a nanobody against HER2 tyrosine kinase using phage display library screening for HER2-positive breast cancer therapy development.
    Lamtha T; Tabtimmai L; Bangphoomi K; Kiriwan D; Malik AA; Chaicumpa W; van Bergen En Henegouwen PMP; Choowongkomon K
    Protein Eng Des Sel; 2021 Feb; 34():. PubMed ID: 34908139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposomal nanoparticle armed with bivalent bispecific single-domain antibodies, novel weapon in HER2 positive cancerous cell lines targeting.
    Nikkhoi SK; Rahbarizadeh F; Ranjbar S; Khaleghi S; Farasat A
    Mol Immunol; 2018 Apr; 96():98-109. PubMed ID: 29549861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
    Akabani G; Carlin S; Welsh P; Zalutsky MR
    Nucl Med Biol; 2006 Apr; 33(3):333-47. PubMed ID: 16631082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biodistribution of a (67)Ga-labeled anti-TNF VHH single-domain antibody containing a bacterial albumin-binding domain (Zag).
    Morais M; Cantante C; Gano L; Santos I; Lourenço S; Santos C; Fontes C; Aires da Silva F; Gonçalves J; Correia JD
    Nucl Med Biol; 2014 May; 41 Suppl():e44-8. PubMed ID: 24530366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.